Titan sees Braeburn as best partner to secure future of Probuphine
This article was originally published in Scrip
Executive Summary
Titan Pharmaceuticals insists that multiple potential partners were interested in commercializing Probuphine (buprenorphine) in the US and Canada, but the company's executives said they signed a license deal with the startup firm Braeburn Pharmaceuticals to reduce the risk that the opioid addiction therapy delivered by a novel subdermal implant would be de-prioritized by a Big Pharma player.